Delving into the Latest Updates on Loratadine with Synapse

Overview

Basic Info

SummaryClaritin (loratadine) is a medication commonly used to treat allergies such as hay fever and hives. It belongs to the second-generation antihistamine family of medications and is taken orally. While common side effects include dry mouth, sleepiness, and headache, serious side effects such as allergic reactions, seizures, and liver problems are rare. Loratadine is generally considered safe during pregnancy, but its effects have not been well studied in this population. Children under two years of age should not take this medication. Loratadine was patented in 1980 and first became available in 1988. It is listed as an essential medication by the World Health Organization and is available as a generic. In the US, it can be purchased over the counter and was one of the most commonly prescribed medications in 2020, with over 9 million prescriptions.

Drug Type

Small molecule drug

Synonyms

Loratadine (JAN/USP/INN), Loratadine Effervescent, Loratadine Hydrochloride

+ [56]

Target

H1 receptor

Action

antagonists

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [2]

Active Indication

Allergic skin reactionSeasonal rhinitisUpper respiratory tract allergy+ [7]

Inactive Indication

Congestion of nasal mucosa

Originator Organization

Merck & Co., Inc.

Active Organization

Bayer AG

Shanghai Schering Plough Pharmaceutical Co. Ltd.Bayer Healthcare LLC

+ [4]

Inactive Organization

Perrigo Co. Plc

License Organization

Taisho Pharmaceutical Co., Ltd.

Merck & Co., Inc.

Bayer Pharma AG

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (12 Apr 1993),

Rhinitis, Allergic, Seasonal

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC22H23ClN2O2

InChIKeyJCCNYMKQOSZNPW-UHFFFAOYSA-N

CAS Registry79794-75-5

This phase IV trial compares the effect of premedication regimens with methylprednisolone versus dexamethasone for the prevention of allergic reaction to motixafortide in patients with multiple myeloma (MM) undergoing stem cell mobilization. MM patients that receive an autologous stem cell transplantation (ASCT) have better outcomes. However, not all MM patients are able to have a successful stem cell mobilization and collection which is needed to proceed to ASCT. The addition of motixafortide prior to stem cell mobilization has allowed more MM patients to collect the needed number of stem cells to proceed to ASCT. However, motixafortide does produce systemic and injection site reactions in many patients. A premedication regimen with dexamethasone prior to motixafortide decreases the incidence of allergic reaction in many patients and is considered the standard of care regimen for the prevention of allergic reaction to motixafortide in patients with MM undergoing stem cell mobilization. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen side effects/allergic reactions. However, dexamethasone is associated with other side effects like headache, difficulty sleeping, high blood glucose, high blood pressure, mood changes, fluid retention, and infection, among others. Thus, the optimal premedication regimen to prevent allergic reactions with motixafortide while avoiding other side effects remains uncertain. It is thought a premedication regimen with methylprednisolone prior to motixafortide may work better to decrease the incidence of reactions to motixafortide in patients with MM undergoing stem cell mobilization. Methylprednisolone is in a class of medications called corticosteroids. It works to decrease side effects/allergic reactions by changing the way the immune system works. Giving methylprednisolone may be safe, tolerable and/or more effective than dexamethasone as part of a premedication regimen for the prevention of allergic reaction to motixafortide in patients with MM undergoing stem cell mobilization.

Start Date01 Aug 2025

Sponsor / Collaborator

Emory University

[+1]

NCT06955741

/ Active, not recruitingPhase 1

A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Healthy Participants

The purpose of this study is to assess drug levels, tolerability and absolute biological availability of single subcutaneous dose of BMS-986446 in healthy participants

Start Date05 May 2025

Sponsor / Collaborator

Bristol Myers Squibb Co.

CTR20244960

/ CompletedNot Applicable

氯雷他定片在健康受试者中空腹条件下开放、随机、单次给药、两制剂、两序列、四周期完全重复交叉设计生物等效性试验

[Translation] An open, randomized, single-dose, two-formulation, two-sequence, four-period completely repeated crossover bioequivalence study of loratadine tablets in healthy subjects under fasting conditions

研究空腹状态下单次口服受试制剂（氯雷他定片，规格10mg，华益药业科技（安徽）有限公司持证）与参比制剂（氯雷他定片，规格10mg，商品名：开瑞坦，拜耳医药（上海）有限公司持证）在健康受试者体内的药代动力学特征，比较受试制剂与参比制剂的生物等效性，并研究药物在健康受试者体内的安全性。

[Translation]

To study the pharmacokinetic characteristics of the test preparation (loratadine tablets, specification 10 mg, licensed by Huayi Pharmaceutical Technology (Anhui) Co., Ltd.) and the reference preparation (loratadine tablets, specification 10 mg, trade name: Claritin, licensed by Bayer Pharmaceuticals (Shanghai) Co., Ltd.) after a single oral administration in healthy subjects under fasting state, compare the bioequivalence of the test preparation and the reference preparation, and study the safety of the drug in healthy subjects.

Start Date15 Feb 2025

Sponsor / Collaborator

Huayi Pharmaceutical Technology (Anhui) Co., Ltd.

100 Clinical Results associated with Loratadine

Login to view more data

100 Translational Medicine associated with Loratadine

Login to view more data

100 Patents (Medical) associated with Loratadine

Login to view more data

3,263

Literatures (Medical) associated with Loratadine

01 Sep 2025·JOURNAL OF HAZARDOUS MATERIALS

Antiallergic drugs drive the alteration of microbial community and antibiotic resistome in surface waters: A metagenomic perspective

Article

Author: Jiang, Hong-Yu ; Ma, Hao ; Shao, Kai-Jie ; Zhang, Chong-Miao ; Li, Yong-Qiang ; Yuan, Pei-Hua

Antiallergic drugs (AADs) are emerging contaminants of global concern due to their environmental persistence and potential ecological impacts. This study investigated the effects of seven AADs (chlorpheniramine, diphenhydramine, cetirizine, loratadine, desloratadine, sodium cromoglicate and calcium gluconate) at environmentally relevant concentrations on antibiotic resistome and bacterial community structures in water using microcosm experiments and metagenomic sequencing. The results showed that AADs increased the abundance of antibiotic-resistant bacteria (ARB) by 1.24- to 7.78-fold. Community structure shifts indicated that chlorpheniramine, diphenhydramine, and cetirizine promoted Actinobacteria (e.g., Aurantimicrobium), while the other four AADs favored Proteobacteria (e.g., Limnohabitans). AADs also significantly altered the relative abundance of antibiotic resistance genes (ARGs), with Actinobacteria and Proteobacteria identified as key ARB components and potential hosts of ARGs (e.g., evgS, mtrA, RanA). Host analysis showed ARGs were primarily carried by Actinobacteria (e.g., Aurantimicrobium) under chlorpheniramine, diphenhydramine, and cetirizine exposure, but by Proteobacteria (e.g., Limnohabitans) under the other four AADs. Furthermore, AADs facilitated the horizontal transfer of ARGs (e.g., evgS) within microbial communities, contributing to antibiotic resistance dissemination. This study highlights the ecological risks of AADs in promoting antibiotic resistance spread and provides new insights into their impact on microbial communities and resistome dynamics in aquatic environments.

16 Jul 2025·BIOLOGICAL & PHARMACEUTICAL BULLETIN

Second-Generation H<sub>1</sub>-Receptor Antagonists, Mequitazine, Azelastine and Desloratadine Activate Caspase-8, Caspase-3, and Gasdermin E and Induce Cell Death Showing Pyroptotic-Like Features in Macrophages at Excessively High Concentrations

Article

Author: Ito, Akane ; Nakajima, Mitsunari ; Sawamoto, Atsushi ; Okuyama, Satoshi

Histamine H₁ receptor (H₁R) is expressed in various cells, including neurons, smooth muscle cells, hepatocytes, T and B cells, neutrophils, dendritic cells, monocytes, and macrophages. Antagonists that target the H₁R are used to relieve the symptoms of allergy and inflammation. Here, we examined the inflammation-modulating and cell death-inducing effects of 10 second-generation H₁R antagonists on mouse intraperitoneal macrophages, which include ketotifen, mequitazine, azelastine, oxatomide, epinastine, bepotastine, fexofenadine, loratadine, levocetirizine, and desloratadine, to assess an anticipated adverse reaction. Three of these antagonists, namely, mequitazine, azelastine, and desloratadine, induced the secretion of interleukin-1α (IL-1α), a marker of pyroptosis and an inflammatory cytokine, from the macrophages at excessively high concentrations, while reducing the secretion of another inflammatory cytokine, IL-6. We found that the macrophages treated with the 3 antagonists showed pyroptotic-like, but not apoptotic-like, morphology and died. Western blotting analysis revealed that caspase-8, caspase-3, and gasdermin E (GSDME), but not gasdermin D, were cleaved and activated in the macrophages. These results suggest that second-generation H₁R antagonists such as mequitazine, azelastine, and desloratadine induce pyroptotic-like cell death accompanied by caspase-8, caspase-3, and GSDME activation in macrophages.

03 Jul 2025·SEPARATION SCIENCE AND TECHNOLOGY

Design, development and practical implementation of a pilot scale plug-and-play tertiary treatment unit for persistent micropollutant degradation from real life pharmaceutical effluents

Author: Mukherjee, Anupam ; Chalichimaala, Srinath ; Roy, Anirban ; Moulik, Siddhartha ; Jayakrishnan, U ; Roy, Subhankar ; Mishra, Birupakshya

Despite the remarkable progress in wastewater treatment strategies over the past decades, the degradation of micro-pollutants still remains a challenging domain to explore, and often, the treated effluent is disposed of without taking care of the same.In this study, a conical plug-and-play reactor (CPPR) was designed to be retrofitted into the existing tertiary treatment point for treating real-life pharmaceutical effluents.Two pharmaceutical effluents (sample I/II) from different treatment plants were treated in CPPR by optimizing the operational parameters and conjugating with other oxidizing agents.The standalone CPPR resulted in the highest COD reduction of 34% and 37% for samples I and II at the optimized values of 2400 rpm, 150 passes, and pH 2.0.The CPPR conjugated with advanced oxidation processes showed an optimal COD reduction of 84%, 81%, and 90% for sample I and 87%, 84%, and 92% for sample II at 0.3 g/L of H₂O₂, 1:3 Fe2+:H2O2 ratio, and 3 g/h of O3 loading, resp.From an energetic and economic point of view, the performance of HC+O3 surpassed that of other oxidizing agents.Further, the techno-economic feasibility was demonstrated with a break-even anal. for financial estimations of potential pilot-scale incorporation of this technol.

22

News (Medical) associated with Loratadine

09 Apr 2024

·www.fiercepharma.com

Bayer taps new North America marketing chief for consumer health division

“I’m excited to leverage my passion for building consumer-led, purpose-driven brands across the Consumer Health portfolio, which includes many brands that I know and love, like Claritin, Aspirin, and Midol,” Samantha Avivi said in this week's announcement. In yet another C-suite shift for Bayer’s consumer health business, the division’s North America segment has appointed a new chief marketing officer. Samantha Avivi is slated to take over the role from Jeff Jarrett, Bayer announced Tuesday. Jarrett had served as marketing chief for Bayer Consumer Health’s North America region since mid-2020—a year after he joined the pharma—and is planning to retire from the company at the end of May. In a LinkedIn post Tuesday, Jarrett called his departure “truly bittersweet,” as he cited the “incredible journey” of working at Bayer while noting that “after five years at Bayer, and nearly 55 years of life, I’m ready for the next chapter… whatever it may hold!” Jarrett also congratulated Avivi on taking the reins, writing, “I’m confident her breadth of experience across so many world-class agencies and companies will bring tremendous value to our brand-building strategy and capabilities moving forward.” Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble, and at agencies including BBDO, Young & Rubicam (now part of VMLY&R) and DMB&B, prior to its acquisition by Publicis. In her new position, Avivi will spearhead North American marketing efforts for Bayer’s range of consumer brands. She’ll report to Dave Tomasi, president of Consumer Health, North America for Bayer. “I’m excited to leverage my passion for building consumer-led, purpose-driven brands across the Consumer Health portfolio, which includes many brands that I know and love, like Claritin, Aspirin, and Midol,” she said in the announcement. Avivi’s appointment is the latest in a spate of recent executive moves for Bayer’s consumer health department. Her new boss, Tomasi—also a Procter & Gamble alum—took on the president role just last summer, following three years as chief commercial officer for the North American consumer health segment. And earlier this year, Bayer announced a new head of the global consumer health business: Julio Triana, currently head of international commercial operations in Bayer’s pharma division, who’s set to take over the president title from Heiko Schipper on May 1. Those high-level switch-ups have taken place as Bayer continues to stave off calls for a separation of the consumer health business. During an investor day last month, CEO Bill Anderson said the company had considered selling off the division but has so far decided against it because of the sizable tax losses such a separation would bring and because the consumer health brands are still generating sold cash flow, among other reasons. This year, Bayer is expecting consumer health sales to grow between 3% and 6% while forecasting that pharma will stay flat or drop up to 4%.

Executive Change

09 Apr 2024

·www.biospace.com

Bayer’s Consumer Health Division Announces Changes to North America Leadership Team

Samantha Avivi appointed as new Chief Marketing Officer of Consumer Health, North America division. Current CMO Jeff Jarrett to retire after five years with Bayer. WHIPPANY, N.J.--(BUSINESS WIRE)-- Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America. She will report directly to Dave Tomasi, President, Consumer Health, North America for Bayer. Avivi will succeed Jeff Jarrett, who is retiring from the company at the end of May. This press release features multimedia. View the full release here: Samantha Avivi (Photo: Business Wire) “I’m pleased to welcome Samantha to Team Bayer to lead our North America marketing organization and join our efforts to achieve ‘Health for all, Hunger for none,‘” said Tomasi. “She has expertise in setting groundbreaking visions, igniting breakthrough growth, accelerating multifunctional teams, with a proven track record of growing businesses, brands and most importantly, people.” “I also want to sincerely thank Jeff Jarrett for his dedication to the company, to our mission, and to our people,” continued Tomasi. “He’s been a driver of innovation, a champion of marketing excellence, a key leader in advancing the turnaround of our Consumer Health business, and a huge advocate for Diversity, Equity & Inclusion at Bayer. While he is leaving Bayer, the friendships he’s forged here will continue, and I wish him all the best in this exciting next chapter.” Samantha has over 25 years of client, retail and agency experience at some of the world’s largest companies like P&G, Kimberly Clark, Walmart, BBDO and Y&R. She was most recently the Chief Marketing Officer at Advance Auto Parts where she owned and executed the company’s omnichannel strategy and operations including a comprehensive marketing vision, philosophy, and plan. During her tenure, she inspired forward-looking programs in support of Advance Auto Parts and its portfolio of brands. “I’m honored to take this leadership role with Bayer, a world leading company with a meaningful mission,” said Avivi. “I’m excited to leverage my passion for building consumer-led, purpose-driven brands across the Consumer Health portfolio, which includes many brands that I know and love, like Claritin, Aspirin, and Midol.” Prior to Advance Auto Parts, Samantha was the CMO at Tenneco, where she led a portfolio of 31 brands across 42 product lines in 26 countries. Samantha is a graduate of the University of Florida with a Bachelor of Business Administration (BBA). About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to bayer.com.

Executive Change

09 Jan 2024

·synapse.patsnap.com

Deciphering H1 receptor antagonists and Keeping Up with Their Recent Developments

The H1 receptor, also known as the histamine H1 receptor, plays a crucial role in the human body. It is primarily found in smooth muscle cells, endothelial cells, and nerve cells. Activation of the H1 receptor by histamine leads to various physiological responses, including vasodilation, increased vascular permeability, bronchoconstriction, and stimulation of sensory nerve endings. These responses are involved in allergic reactions, inflammation, and immune responses. Antagonists of the H1 receptor, commonly known as antihistamines, are widely used to treat allergies, hay fever, and other conditions associated with excessive histamine release. Understanding the role of the H1 receptor is essential for developing effective treatments for allergic and inflammatory disorders. The analysis of the target H1 receptor reveals a competitive landscape with multiple companies actively developing drugs. GSK Plc, Sanofi, Pfizer Inc., Bayer AG, and Novartis AG are among the companies with the highest number of approved drugs or drugs in advanced stages of development. The indications with the most approved drugs include Common Cold, Rhinitis, Allergic, Urticaria, Pruritus, and Hypersensitivity. Small molecule drugs are the most rapidly progressing drug type, indicating intense competition in this area. China, the United States, and Japan are the countries with the highest number of approved drugs, with China showing significant progress in the development of drugs targeting the H1 receptor. Overall, the target H1 receptor presents opportunities for further research and development, particularly in indications with high unmet medical needs. How do they work?H1 receptor antagonists, also known as H1 blockers or antihistamines, are a class of drugs that block the action of histamine at the H1 receptor. Histamine is a chemical released by the body during an allergic reaction, causing symptoms such as itching, sneezing, runny nose, and watery eyes. H1 receptor antagonists work by binding to the H1 receptors on cells, preventing histamine from binding and exerting its effects. From a biomedical perspective, H1 receptor antagonists are commonly used to treat allergic conditions, such as hay fever (allergic rhinitis), hives (urticaria), and allergic conjunctivitis. They help alleviate symptoms by reducing the effects of histamine, thereby relieving itching, sneezing, and other allergic reactions. There are different generations of H1 receptor antagonists, each with varying degrees of sedative effects. First-generation antihistamines, such as diphenhydramine and chlorpheniramine, can cause drowsiness and are often used for their sedative properties in addition to their antihistamine effects. Second-generation antihistamines, such as cetirizine, loratadine, and fexofenadine, are less likely to cause sedation and are preferred for daytime use. In summary, H1 receptor antagonists are drugs that block the action of histamine at the H1 receptor, providing relief from allergic symptoms. They are commonly used in the treatment of various allergic conditions and come in different generations with varying sedative effects. List of H1 receptor AntagonistsThe currently marketed H1 receptor antagonists include: Olopatadine Hydrochloride/Mometasone Furoate MonohydrateChlorpheniramine Maleate/Codeine PhosphateDiphenhydramine Hydrochloride/Naproxen SodiumRecombinant interferon alfa-2b/LoratadineRupatadine FumarateAzelastine/mometasoneEbastine/Pseudoephedrine HydrochlorideAzelastine Hydrochloride/Fluticasone PropionateChlorpheniramine Maleate/Hydrocodone Bitartrate/Pseudoephedrine HydrochlorideAlcaftadineFor more information, please click on the image below. What are H1 receptor antagonists used for?H1 receptor antagonists are widely used to treat allergies, hay fever, and other conditions associated with excessive histamine release. For more information, please click on the image below to log in and search. How to obtain the latest development progress of H1 receptor antagonists?In the Synapse database, you can keep abreast of the latest research and development advances of H1 receptor antagonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

100 Deals associated with Loratadine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00364	Loratadine	R06AX13	DB00455

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Allergic skin reaction	New Zealand	AFT Pharmaceuticals Ltd.	20 Jul 2011
Seasonal rhinitis	New Zealand	AFT Pharmaceuticals Ltd.	20 Jul 2011
Upper respiratory tract allergy	United States	Taro Pharmaceuticals, Inc.	04 Oct 2005
Perennial allergic rhinitis with seasonal variation	Australia	Alphapharm Pty Ltd.	15 Mar 2005
Respiratory Hypersensitivity	United States	Perrigo Co. Plc	24 Jun 2004
Dermatitis	Japan	Bayer Yakuhin Ltd.	27 Feb 2004
Eczema	Japan	Bayer Yakuhin Ltd.	27 Feb 2004
Urticaria	Japan	Bayer Yakuhin Ltd.	27 Feb 2004
Rhinitis, Allergic	China	Shanghai Schering Plough Pharmaceutical Co. Ltd.	01 Jan 1997
Rhinitis, Allergic	China	Bayer AG	01 Jan 1997
Chronic Urticaria	United States	Bayer Healthcare LLC	10 Oct 1996
Rhinitis, Allergic, Seasonal	United States	Bayer Healthcare LLC	12 Apr 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Congestion of nasal mucosa	Phase 3	-	Bayer AG	01 Aug 2011
Anaphylaxis	Phase 1	Germany	Bayer AG	01 Dec 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04248712 (ATEE, CTgov)	Phase 2	Eosinophilic Esophagitis	1	Famotidine+Loratadine (Treatment Group)	zmsctvrqgd = zpublvkjod wnktljbxnt (qwmaxuvffj, ywjkudyoxw - lynztiwstc) View more	-	20 Dec 2022
				Placebo (Placebo Group)	krptkxxemg(nluxjgmrjk) = fbqpptyuhz kaoalamwuv (enjmkqtiuv, dtgvbyxuni - jzccxfayke) View more
NCT04162795 (CTgov)	Phase 4	Upper respiratory tract allergy \| Rhinitis, Allergic	468	Loratadine	evtnefpvro = jradovrrdc zhgmclkpqy (vgnhmiobzd, pftgkgejxm - ujkqbksxke) View more	-	04 Feb 2021
ESMO_ASIA_VIRTUAL2020	Not Applicable	-	814	Loratadine	jzyxsauxjh(mpiwkkxalx) = zrfsqyjvky xknfprhvpe (hndkfkwyqy )	Negative	22 Nov 2020
				loratadine (Control)	jzyxsauxjh(mpiwkkxalx) = gdpyfiyczn xknfprhvpe (hndkfkwyqy )
NCT03855228 (C94-145, CTgov)	Phase 3	Rhinitis, Allergic, Seasonal	704	Placebo nasal spray+Loratadine (Loratadine 10 mg)	vqnrkgsmbs(dvsgopkntp) = uxcilmxphy xqnccqgyht (ttwrflalov, 2.2) View more	-	26 Jul 2019
				Placebo nasal spray (Placebo)	vqnrkgsmbs(dvsgopkntp) = ybrevfjgkt xqnccqgyht (ttwrflalov, 2.1) View more
NCT01451996 (CTgov)	Phase 4	-	340	Claritin (Claritin Ads, Allergy+)	ktkikzcgmt(bmveuydtns) = tznydxtras uccnimtqwu (chwposuzim, 2.5) View more	-	13 Mar 2018
				Zyrtec Ads (Zyrtec Ads, Allergy+)	ktkikzcgmt(bmveuydtns) = gxurwcredh uccnimtqwu (chwposuzim, 2.5) View more
NCT01311336 (Pubmed \| Support Care Cancer)	Phase 2	Ostealgia	-	Loratadine 10 mg	nhpnillcbk(aphxgonezx) = oipwypbwmo pnuaahcnck (tcjqywovit ) View more	-	01 Jul 2016
				Placebo	nhpnillcbk(aphxgonezx) = rfobwfmkle pnuaahcnck (tcjqywovit )
NCT01712009 (NOLAN, CTgov)	Phase 2	Breast Cancer \| Ostealgia	600	pegfilgrastim (No Prophylaxis)	dewzlisktw = guuhhoillw xgwrzwalkv (tjbqtdqumv, hmgpkfwcrs - kyrdxfelye) View more	-	09 Mar 2016
				Naproxen (Naproxen 500 mg BID)	dewzlisktw = bcwkzluffo xgwrzwalkv (tjbqtdqumv, hwnkccoosw - rcotxzfxnh) View more
NCT01469234 (P08712, CTgov)	Phase 4	Rhinitis, Allergic, Seasonal	255	placebo to fexofenadine+loratadine (Loratadine)	ejjoeefzzz(sgajjntezi) = gtulaeqyly lsiqkrvxed (dhlaeownes, 4.51) View more	-	22 Mar 2013
				placebo to loratadine+fexofenadine (Fexofenadine)	ejjoeefzzz(sgajjntezi) = dpqrbpesij lsiqkrvxed (dhlaeownes, 4.86) View more
NCT01413958 (P08498, CTgov)	Phase 3	Rhinitis, Allergic, Seasonal \| Congestion of nasal mucosa	575	phenylephrine+Loratadine (Phenylephrine)	avjxbtqpeg(xcwituccxf) = bdlzrdzqds bdzbvzjwgi (yerdxkjwuf, 0.5203) View more	-	29 Jan 2013
				Placebo+Loratadine (Placebo)	avjxbtqpeg(xcwituccxf) = rbzwlatgql bdzbvzjwgi (yerdxkjwuf, 0.5586) View more
NCT01330017 (P08156, CTgov)	Phase 2	Rhinitis, Allergic, Seasonal \| Seasonal rhinitis \| Congestion of nasal mucosa	539	Placebo+Phenylephrine HCl+Loratadine (PE 10 mg)	bljvnngzqs(zvbcayrzno) = mwmghpmobq xircgobuoe (asoungrgri, 0.5374) View more	-	07 Nov 2012
				Placebo+Phenylephrine HCl+Loratadine (PE 20 mg)	bljvnngzqs(zvbcayrzno) = blsrfmayit xircgobuoe (asoungrgri, 0.5042) View more